Gilead Sciences

Up on Deck! Ten Q3 Biotech Earnings Reports to Watch Next Week
Up on Deck! Ten Q3 Biotech Earnings Reports to Watch Next Week
BioSpace
earnings
biotech
Biogen
Alexion Pharmaceuticals
Bristol-Myers Squibb
Celgene
Gilead Sciences
Merck
Biomarin
Galapagos
Seattle Genetics
Dr Reddy's
Flag link:
Gilead, Aelix ally to trial HIV-suppressing combination
Gilead, Aelix ally to trial HIV-suppressing combination
Fierce Biotech
Gilead Sciences
Aelix Therapeutics
vaccines
antiretrovirals
HIV
Flag link:
7 drugmakers to watch during Q3 earnings
7 drugmakers to watch during Q3 earnings
Biopharma Dive
earnings
Novartis
Gilead Sciences
Amgen
Pfizer
GSK
AbbVie
Regeneron
Flag link:
NHS, Gilead reach agreement for Yescarta
NHS, Gilead reach agreement for Yescarta
BioCentury
Yescarta
Gilead Sciences
UK
NHS
CAR-T
Flag link:
Gilead Sciences’ Biktarvy shows high efficacy in HIV-1 study
Gilead Sciences’ Biktarvy shows high efficacy in HIV-1 study
Pharmaceutical Business Review
Gilead Sciences
Biktarvy
HIV-1
HIV
Flag link:
Gilead's FXR agonist among NASH therapies highlighted ahead of AASLD
Gilead's FXR agonist among NASH therapies highlighted ahead of AASLD
BioCentury
Gilead Sciences
NASH
GS-9674
FXR agonists
Flag link:
Merck asks SCOTUS for its $200M in Gilead patent dues, never mind the misconduct
Merck asks SCOTUS for its $200M in Gilead patent dues, never mind the misconduct
Fierce Pharma
Merck
Supreme Court
Gilead Sciences
hepatitis C
Flag link:
AbbVie's not the only one facing kickbacks scrutiny. Add Biogen, Sanofi, Gilead and more
AbbVie's not the only one facing kickbacks scrutiny. Add Biogen, Sanofi, Gilead and more
Fierce Pharma
AbbVie
Biogen
Sanofi
Gilead Sciences
Flag link:
Express Scripts praises, then takes credit for Gilead's authorized generics launches
Express Scripts praises, then takes credit for Gilead's authorized generics launches
Fierce Pharma
Gilead Sciences
Express Scripts
generics
hepatitis C
Flag link:
Gilead to Launch Authorized Generic Versions of Epclusa and Harvoni for Chronic Hepatitis C
Gilead to Launch Authorized Generic Versions of Epclusa and Harvoni for Chronic Hepatitis C
CP Wire
Gilead Sciences
generics
Epclusa
Harvoni
hepatitis C
Asegua Therapeutics
Flag link:
Galapagos opposes takeover attempt by Gilead
Galapagos opposes takeover attempt by Gilead
GoinPharma
Galapagos
Gilead Sciences
M&A
Flag link:
A Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis
A Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis
Yahoo/Motley Fool
AbbVie
Gilead Sciences
FDA
rheumatoid arthritis
Upadacitinib
filgotinib
Flag link:
What's Next for Gilead Sciences After Its Latest Clinical Success
What's Next for Gilead Sciences After Its Latest Clinical Success
Motley Fool
Gilead Sciences
John Milligan
HIV
NASH
filgotinib
Flag link:
Galapagos shares surge on RA drug trial results
Galapagos shares surge on RA drug trial results
Pharmaforum
Gilead Sciences
Galapagos
filgotinib
rheumatoid arthritis
clinical tgrials
Flag link:
Skirting a group of pioneers, Gilead partners with gene-editing upstart Precision Bio in hunt to cure hep B
Skirting a group of pioneers, Gilead partners with gene-editing upstart Precision Bio in hunt to cure hep B
Endpoints
Gilead Sciences
hepatitis B
gene editing
Precision Biosciences
Flag link:
Gilead, Galapagos clear another PhII hurdle for filgotinib, but can they hope to catch up with Novartis’ Cosentyx?
Gilead, Galapagos clear another PhII hurdle for filgotinib, but can they hope to catch up with Novartis’ Cosentyx?
Endpoints
Gilead Sciences
Galapagos
filgotinib
Novartis
Cosentyx
ankylosing spondylitis
Flag link:
Allogene Therapeutics Banks $120 Million in Private Financing
Allogene Therapeutics Banks $120 Million in Private Financing
CP Wire
Allogene
Gilead Sciences
Pfizer
Flag link:
Gilead steals new commercial chief from Amgen to tackle big sales challenges
Gilead steals new commercial chief from Amgen to tackle big sales challenges
Fierce Pharma
Gilead Sciences
Amgen
Laura Hamill
Flag link:
UK rejects Gilead's CAR-T cancer cell therapy as too expensive
UK rejects Gilead's CAR-T cancer cell therapy as too expensive
Reuters
Yescarta
UK
Europe
CAR-T
NICE
Gilead Sciences
Flag link:
Sierra Oncology Acquires Gilead’s Stalled Myelofibrosis Drug
Sierra Oncology Acquires Gilead’s Stalled Myelofibrosis Drug
Xconomy
Gilead Sciences
Sierrra Oncology
myelofibrosis
momelotinib
Flag link:

Pages